Table 2.
Overall | Preprophylaxis implementation | Postprophylaxis implementation | |||||||
---|---|---|---|---|---|---|---|---|---|
Overall, n (%) | One-year cumulative incidence of TA-TMA, % (95% CI) | P | Overall, n (%) | One-year cumulative incidence of TA-TMA, % (95% CI) | P | Overall, n (%) | One-year cumulative incidence of TA-TMA, % (95% CI) | P | |
Conditioning | .17 | .29 | .02 | ||||||
TBI-MAC | 43 (17) | 12.2 (2.2-22.2) | 32 (20) | 9.8 (0.3-19.3) | 11 (11) | 19.2 (0-43.1) | |||
Non TBI-MAC* | 171 (66) | 5.7 (2-9.4) | 101 (63) | 8.5 (2.8-14.2) | 70 (73) | 1.6 (0-4.7) | |||
RIC or NMA | 43 (17) | 2.4 (0-7.1) | 28 (17) | 0 | 15 (16) | 7.1 (0-20.6) | |||
Stem cell source | .40 | .47 | .86 | ||||||
Bone marrow | 88 (34) | 4.7 (0.2-9.2) | 46 (29) | 4.7 (0-11) | 42 (44) | 4.9 (0-11.6) | |||
PBSCs† | 153 (60) | 7.8 (3.3-12.3) | 106 (66) | 9.1 (3.4-14.8) | 47 (49) | 4.6 (0-10.9) | |||
Cord‡ | 16 (6) | 0 | 9 (5) | 0 | 7 (7) | 0 | |||
Donor type | .13 | .02 | .82 | ||||||
MRD | 60 (23) | 5 (0-10.5) | 32 (20) | 3.1 (0-9.1) | 28 (29) | 7.1 (0-16.7) | |||
MMRD (9/10) | 3 (1) | 0 | 3 (2) | 0 | 0 | — | |||
Haploidentical | 58 (23) | 14.2 (4.4-24) | 31 (19) | 22.1 (6.4-37.8) | 27 (28) | 3.7 (0-10.7) | |||
MUD (10/10) | 92 (36) | 3.4 (0-7.1) | 58 (36) | 3.5 (0-8.4) | 34 (36) | 3.2 (0-9.5) | |||
MMUD (≤9/10) | 44 (17) | 4.9 (0-11.6) | 37 (23) | 5.8 (0-13.6) | 7 (7) | 0 | |||
HLA-mismatch (<10/10) | .08 | .04 | .79 | ||||||
No | 152 (59) | 4.1 (1-7.2) | 90 (56) | 3.4 (0-7.1) | 62 (64) | 5 (0-10.5) | |||
Yes | 105 (41) | 9.9 (3.8-16) | 71 (44) | 12.7 (4.5-20.9) | 34 (36) | 2.9 (0-8.6) | |||
Minor ABO mismatch | .98 | .58 | .27 | ||||||
No | 189 (74) | 6.3 (2.8-9.8) | 115 (71) | 6.5 (1.8-11.2) | 74 (77) | 5.9 (0.4-11.4) | |||
Yes | 68 (26) | 6.3 (0.4-12.2) | 46 (29) | 9.1 (0.7-17.5) | 22 (23) | 0 | |||
Pre-HSCT CNI exposure | .003 | .02 | .07 | ||||||
No | 238 (93) | 5 (2.1-7.9) | 147 (91) | 5.8 (1.9-9.7) | 91 (95) | 3.6 (0-7.5) | |||
Yes | 19 (7) | 22.4 (3-41.8) | 14 (9) | 22.6 (0.1-45.1) | 5 (5) | 20 (0-55) |
MMRD, mismatched related donor; MMUD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor.
Conditioning regimens for patients with Fanconi anemia were considered MAC.
One patient received PBSC + marrow.
Three patients received cord + marrow.